地西他滨联合HAG方案对MDS患者造血功能及HIF-1α、VEGF水平的影响  

Effect of Decitabine Combined with HAG Regimen on Hematopoietic Function and Serum HIF-1αand VEGF Levels in Patients with MDS

作　　者：闫春梅 白忠旭[2] Yan Chunmei;Bai Zhongxu(Department of Hematology and Oncology,Ninety-eighth Hospital of the Chinese People’s Liberation Army Joint Logistics and Security Forces,Zhengzhou,Henan,450000,China)

机构地区：[1]中国人民解放军联勤保障部队第九八八医院血液肿瘤科,河南郑州450000 [2]郑州市第二人民医院骨科,河南郑州450000

出　　处：《黑龙江医学》2023年第18期2189-2191,2195,共4页Heilongjiang Medical Journal

摘　　要：目的:分析地西他滨联合HAG方案对骨髓增生异常综合征(MDS)患者造血功能及血清低氧诱导因子1α(HIF-1α)、血管内皮生长因子(VEGF)水平的影响。方法:选取2019年1月—2020年12月中国人民解放军联勤保障部队第九八八医院收治的84例MDS患者,采用随机数表法分为对照组42例和观察组42例。对照组采用HAG方案进行治疗,观察组在对照组的基础上采用地西他滨进行治疗,两组患者均治疗2周。统计两组患者治疗2周后的临床疗效,比较两组患者治疗前和治疗2周后造血功能、血清HIF-1α、VEGF水平及生活质量。结果:治疗2周后,观察组客观缓解率(ORR)和疾病控制率(DCR)均显著高于对照组,差异有统计学意义(χ^(2)=4.773、4.043,P<0.05)。与治疗前相比,治疗2周后两组患者血清生长分化因子11(GDF11)、可溶性转铁蛋白(sTfR)、HIF-1α、VEGF水平均降低,且观察组低于对照组,差异有统计学意义(t=20.684、6.111、15.237、5.402,P<0.05)。与治疗前相比,治疗2周后两组患者心理功能、生理功能、日常活动、社会功能评分升高,且观察组高于对照组,差异有统计学意义(t=5.194、5.375、6.814、7.102,P<0.05)。结论:地西他滨联合HAG方案对MDS患者进行治疗,可有效改善患者造血功能,降低血清HIF-1α、VEGF水平,控制患者病情,改善患者生活质量,具有较好的治疗效果。Objective:To analyze the effects of decitabine combined with HAG regimen on hematopoietic function and serum hypoxia-inducible factor 1α(HIF-1α)and vascular endothelial growth factor(VEGF)levels in patients with myelodysplastic syndrome(MDS).Methods:84 patients with MDS admitted to the hospital from January 2019 to December 2020 were selected and divided into a control group(42 cases)and an observation group(42 cases)using the random number table method.The control group was treated with the HAG regimen and the observation group was treated with decitabine on top of the control group,and patients in both groups were treated for 2 weeks.The clinical efficacy of the two groups was counted after 2 weeks of treatment,and the hematopoietic function,serum HIF-1α,VEGF level and quality of life of the two groups were compared before and after 2 weeks of treatment.Results:After 2 weeks of treatment,the objective remission rate(ORR)and disease control rate(DCR)were significantly higher in the observation group than in the control group,with statistically significant differences(χ^(2)=4.773,4.043,P<0.05).Compared with before treatment,serum growth differentiation factor 11(GDF11),soluble transferrin(sTfR),HIF-1αand VEGF levels were reduced in both groups after 2 weeks of treatment,the observation group was lower than the control group,and the difference was statistically significant(t=20.684,6.111,15.237,5.402,P<0.05).Compared with the pre-treatment period,the psychological function,physical function,daily activity,and social function scores increased in both groups after 2 weeks of treatment,the observation group was higher than the control group,and the difference was statistically significant(t=5.194,5.375,6.814,7.102,P<0.05).Conclusion:Decitabine combined with HAG regimen in MDS patients can effectively improve the hematopoietic function of patients,reduce serum HIF-1αand VEGF levels,control patients’disease and improve their quality of life,which has a better therapeutic effect.

关 键 词：骨髓增生异常综合征 地西他滨 造血功能 低氧诱导因子1Α 血管内皮生长因子 

分 类 号：R551.3[医药卫生—血液循环系统疾病]